Allergan Fuels Tension Over Schedule 13D Disclosure
Valeant Pharmaceuticals International Inc. and Pershing Square Capital Management LP's hostile bid for Allergan Inc. seems to have run its course following the announcement of the proposed acquisition of Allergan by...To view the full article, register now.
Already a subscriber? Click here to view full article